for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

JCR Pharmaceuticals Co Ltd

4552.T

Latest Trade

8,770.00JPY

Change

-290.00(-3.20%)

Volume

152,800

Today's Range

8,700.00

 - 

8,970.00

52 Week Range

4,260.00

 - 

9,480.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
9,060.00
Open
8,940.00
Volume
152,800
3M AVG Volume
1.96
Today's High
8,970.00
Today's Low
8,700.00
52 Week High
9,480.00
52 Week Low
4,260.00
Shares Out (MIL)
30.83
Market Cap (MIL)
293,739.50
Forward P/E
63.22
Dividend (Yield %)
0.35

Next Event

Q3 2020 JCR Pharmaceuticals Co Ltd Earnings Release

Latest Developments

More

Mesoblast And JCR Pharmaceuticals Expand Japan License Agreement

Mesoblast Expands Partnership With JCR Pharmaceuticals In Japan

Mesoblast Expands Partnership With JCR Pharmaceuticals

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About JCR Pharmaceuticals Co Ltd

JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Company operates in two segments. The Pharmaceutical segment engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment segment engages in the purchase and sale of the medical and research equipment.

Industry

Biotechnology & Drugs

Contact Info

3-19, Kasuga-cho

+81.797.328591

http://www.jcrpharm.co.jp

Executive Leadership

Shin Ashida

Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer, President of Subsidiary, Representative Director

Hiroshi Yoshimoto

Senior Managing Director, Chief Director of Production, Representative Director

Yuji Sato

Managing Director

Yoshihiko Ohnishi

Executive Officer, Chief Director of Sales, Director of Capital Area Sales in Main Sales Unit

Mamoru Morita

Chief Director of Sales, Director of Tokyo Metropolitan Sales, Director

Key Stats

2.00 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (JPY)

2017

58.950

2018

98.730

2019

120.679

2020(E)

143.315
Price To Earnings (TTM)
86.13
Price To Sales (TTM)
12.18
Price To Book (MRQ)
8.98
Price To Cash Flow (TTM)
63.57
Total Debt To Equity (MRQ)
27.92
LT Debt To Equity (MRQ)
11.90
Return on Investment (TTM)
9.69
Return on Equity (TTM)
7.68

Latest News

Latest News

BRIEF-JCR Pharmaceuticals to set up investigational new drug production center with investment of 3 bln yen

* Says it will set up an investigational new drug production center with investment of about 3 billion yen from March 2019

BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement

* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases

BRIEF-Medipal Holdings signs contract to set up JV JCR USA with JCR Pharmaceuticals

* Says it signed a contract to set up a JV JCR USA Inc with JCR Pharmaceuticals Co Ltd

BRIEF-JCR Pharmaceuticals to initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo

* Says it will initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo

BRIEF-NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

* Says it and NanoCarrier Co., Ltd conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

BRIEF-JCR Pharmaceuticals submits application for marketing approval of JR-051 for Fabry disease

* Says it has submitted an application for marketing approval on JR-051 (recombinant alpha-galactosidase A), an enzyme replacement therapy (ERT) for Fabry disease to Ministry of Health, Labour and Welfare

BRIEF-JCR Pharmaceuticals completes share repurchase through ToSTNeT-3

* Says it completed repurchase of 854,100 shares of its common stock, for 2.62 billion yen in total, through ToSTNeT-3, on Sept. 22

BRIEF- JCR Pharmaceuticals to repurchase shares

* Says it will repurchase up to 940,000 shares of its common stock, representing 2.7 percent of outstanding, on Sept. 22

BRIEF- JCR Pharmaceuticals announces shareholding structure change

* Says its top shareholder GLAXO GROUP LIMITED will cut voting power in the company to 0 percent from 25.2 percent

BRIEF- JCR Pharmaceuticals announces business and capital alliance with Medipal Holdings

* Says it signed a business and capital alliance with Medipal Holdings Corp

BRIEF- JCR Pharmaceuticals to develop allogeneic regenerative medical product using DPCs with Teijin

* Says it entered into co-development and license agreement with Teijin Ltd, regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan, on July 18

BRIEF-JCR Pharmaceuticals to dissolve Hebei-based subsidiary

* Says it plans to dissolve Hebei province-based subsidiary, which is engaged in pharmaceutical business

BRIEF-JCR Pharmaceuticals initiates phase 1/2 clinical trial of jr-141 in hunter syndrome

* Says co initiates phase 1/2 clinical trial of jr-141 in hunter syndrome

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up